SL-176

Overview

SL-176 is a PPM1D ( Wip1 ) inhibitor. SL-176 inhibits lipid droplet formation, downregulates the mRNA and protein expression of PPARγ and C/EBPα , and blocks adipocyte differentiation. SL-176 induces G2/M cell cycle arrest, apoptosis and inhibits cell proliferation in breast cancer cells overexpressing PPM1D , and activates components of the p53 pathway. SL-176 suppresses tumor growth in a zebrafish model of neuroblastoma. SL-176 is applicable to research related to obesity, breast cancer and neuroblastoma.

Application

Products | Products > Disease Areas > Lipid Metabolism | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Obesity | Products > Disease Areas > Cancer | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Metabolic Disease | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Phosphatase | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > MDM-2/p53 | Products > Signaling Pathways > Caspase

Product Information

• Catalog No.: HY-172609
• CAS No.: 1809556-48-6
• Molecular Formula: C24H48O4Si2
• Molecular Weight: 456.81
• Purity: 99.91%
• Storage: Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.5 mg/mL (5.47 mM); Clear solution
• Availability: In-stock

Source

Original product source